Liposarcoma Clinical Trials

14 recruiting

Liposarcoma Trials at a Glance

27 actively recruiting trials for liposarcoma are listed on ClinicalTrialsFinder across 6 cities in 22 countries. The largest study group is Phase 1 with 14 trials, with the heaviest enrollment activity in Houston, St Louis, and Boston. Lead sponsors running liposarcoma studies include National Cancer Institute (NCI), Baylor College of Medicine, and Australia and New Zealand Sarcoma Association.

Browse liposarcoma trials by phase

Treatments under study

About Liposarcoma Clinical Trials

Looking for clinical trials for Liposarcoma? There are currently 14 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Liposarcoma trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Liposarcoma clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 27 trials

Recruiting
Phase 3

Measuring if Immunotherapy Plus Chemotherapy is Better Than Chemotherapy Alone for Patients With Aggressive Poorly Differentiated Sarcomas

Metastatic Dedifferentiated LiposarcomaStage III Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8Stage IV Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8+3 more
National Cancer Institute (NCI)365 enrolled248 locationsNCT06422806
Recruiting
Phase 1Phase 2

STC-15 as a Part of Combination Therapy With Toripalimab in Selected Advanced Cancers and as Monotherapy in Participants With Selected Sarcomas

SarcomaSolid TumorLeiomyosarcoma+1 more
STORM Therapeutics LTD107 enrolled6 locationsNCT06975293
Recruiting
Phase 1Phase 2

NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS)

AngiosarcomaLiposarcomaAdipocytic Neoplasm+6 more
St. Jude Children's Research Hospital139 enrolled6 locationsNCT06239272
Recruiting
Phase 1

Phase I/Ib Study of NK Expressing an Affinity-enhanced T-cell Receptor (TCR) Against the NY-ESO-1

Synovial SarcomaMyxoid/Round Cell Liposarcoma
M.D. Anderson Cancer Center44 enrolled1 locationNCT06083883
Recruiting
Phase 1Phase 2

Testing the Addition of an Anti-cancer Drug, Abemaciclib, to the Usual Chemotherapy Treatment (Gemcitabine) for Soft Tissue Sarcoma

Metastatic Soft Tissue SarcomaMetastatic LeiomyosarcomaAdvanced Soft Tissue Sarcoma+5 more
National Cancer Institute (NCI)74 enrolled1 locationNCT06498648
Recruiting
Phase 1

Testing Low-Dose Common Chemotherapy (Liposomal Doxorubicin) in Combination With an Anti-Cancer Drug, Peposertib, in Advanced Sarcoma

Metastatic SarcomaMetastatic LeiomyosarcomaUnresectable Leiomyosarcoma+9 more
National Cancer Institute (NCI)30 enrolled16 locationsNCT05711615
Recruiting
Phase 1Phase 2

Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors

OsteosarcomaEwing SarcomaNeuroblastoma+2 more
Milton S. Hershey Medical Center104 enrolled21 locationsNCT06541262
Recruiting
Phase 1

Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor Expressed in T Cells for Pediatric Solid Tumors

Liver CancerRhabdomyosarcomaWilms Tumor+3 more
Baylor College of Medicine24 enrolled1 locationNCT04715191
Recruiting
Phase 3

Surgery With or Without Neoadjuvant Chemotherapy in High Risk RetroPeritoneal Sarcoma

LeiomyosarcomaRetroperitoneal SarcomaLiposarcoma
European Organisation for Research and Treatment of Cancer - EORTC250 enrolled164 locationsNCT04031677
Recruiting
Phase 1Phase 2

A Study of Mirdametinib in Combination With Palbociclib in People With Liposarcoma

LiposarcomaDedifferentiated LiposarcomaPleomorphic Liposarcoma+6 more
Memorial Sloan Kettering Cancer Center54 enrolled7 locationsNCT06843967
Recruiting

Precision Medicine Approaches for Neoadjuvant Therapy in High-risk Sarcoma Patients

SarcomaAngiosarcomaSoft Tissue Sarcoma (STS)+9 more
Royal Marsden NHS Foundation Trust800 enrolled1 locationNCT07432932
Recruiting
Phase 1

Immunotherapy for Solid Tumor Malignancies in Pediatrics Using Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor T Cells

Hepatocellular CarcinomaRhabdomyosarcomaWilms Tumor+7 more
Seattle Children's Hospital21 enrolled1 locationNCT07148050
Recruiting
Phase 2

Dose-escalated, Hypofractionated, Definitive Proton Radiotherapy for Patients With Inoperable Soft Tissue Sarcoma.

Soft Tissue Sarcoma (STS)Soft Tissue Sarcoma AdultSynovial Sarcomas+7 more
Oslo University Hospital40 enrolled2 locationsNCT07173972
Recruiting
Phase 2

Hypofractionated, 3-week, Preoperative Proton or X-ray Radiotherapy for Patients With Localized Soft Tissue Sarcoma

Soft Tissue Sarcoma AdultLeiomyosarcomaSynovial Sarcomas+6 more
Oslo University Hospital110 enrolled4 locationsNCT07169344
Recruiting

Prospective Study Evaluating the Treatment Outcomes for Localised Recurrent, Resectable Retroperitoneal Liposarcoma

Retroperitoneal Liposarcoma
Australia and New Zealand Sarcoma Association100 enrolled9 locationsNCT07377747
Recruiting
Phase 2

IO Combined With AI as First-line Treatment for Patients With Soft Tissue Sarcoma(TAIS)

AngiosarcomaLeiomyosarcomaDesmoplastic Small Round Cell Tumor+4 more
Fudan University45 enrolled1 locationNCT06849986
Recruiting
Phase 1

Immunotherapy For Adults With GPC3-Positive Solid Tumors Using IL-15 and IL-21 Armored GPC3-CAR T Cells

Hepatocellular CarcinomaRhabdomyosarcomaWilms Tumor+5 more
Baylor College of Medicine21 enrolled1 locationNCT06198296
Recruiting
Phase 1

BTX-A51 in Patients With Liposarcoma or CIC-rearranged Sarcoma

LiposarcomaMyxoid LiposarcomaRecurrent Liposarcoma+4 more
Michael Wagner, MD24 enrolled2 locationsNCT06414434
Recruiting
Phase 1

Zanzalintinib Combined With Eribulin in Advanced Liposarcoma and Leiomyosarcoma

Advanced LeiomyosarcomaAdipocytic SarcomaAdvanced Liposarcoma
Washington University School of Medicine18 enrolled1 locationNCT06957431
Recruiting
Phase 2

A Phase 2, Open Label Study of PEmigatinib and REtifanlimab in Advanced Dedifferentiated LIposarcoma (PERELI)

Dedifferentiated Liposarcoma
Lund University Hospital33 enrolled4 locationsNCT06389799